Emerging novel concept of chaperone therapies for protein misfolding diseases

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Protein misfolding diseases, including lysosomal storage disorders, are characterized by unstable mutant proteins leading to loss of function.
• Current therapeutic strategies are limited, necessitating novel approaches for protein misfolding conditions.

Purpose of the Study:

• To explore chaperone therapy as a molecular therapeutic strategy for protein misfolding diseases.
• To investigate the potential of small molecule chaperones to stabilize mutant proteins and restore function.
• To evaluate the efficacy of chaperone therapy in preclinical models of lysosomal and neurodegenerative diseases.

Main Methods:

• Utilizing active-site binding low molecular competitive inhibitors (chemical chaperones) to stabilize misfolded enzyme proteins.
• Administering chemical chaperones orally to assess their ability to cross the blood-brain barrier and correct disease pathophysiology.
• Investigating molecular chaperone therapy using heat shock proteins and other chaperone proteins induced by small molecules.

Main Results:

• Chemical chaperones paradoxically stabilized and enhanced enzyme activity by correcting protein misfolding in somatic cells.
• Oral administration of chaperones allowed them to reach the brain and ameliorate disease pathophysiology.
• Experimental trials using heat shock protein-inducing molecules showed promise for managing abnormally accumulated proteins in neurodegenerative diseases.

Conclusions:

• Chaperone therapy, encompassing chemical and molecular approaches, represents a promising therapeutic avenue for a wide range of diseases.
• This strategy holds potential for treating lysosomal, genetic, neurological, and non-neurological disorders characterized by protein misfolding or accumulation.